|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Munkarah A, Chatterjee M and Tainsky MA:
Update on ovarian cancer screening. Curr Opin Obstet Gynecol.
19:22–26. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tinelli A, Vergara D, Martignago R, Leo G,
Pisanò M and Malvasi A: An outlook on ovarian cancer and borderline
ovarian tumors: Focus on genomic and proteomic findings. Curr
Genomics. 10:240–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lowe KA, Chia VM, Taylor A, O'Malley C,
Kelsh M, Mohamed M, Mowat FS and Goff B: An international
assessment of ovarian cancer incidence and mortality. Gynecol
Oncol. 130:107–114. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Davis A, Tinker AV and Friedlander M:
'Platinum resistant' ovarian cancer: What is it, who to treat and
how to measure benefit? Gynecol Oncol. 133:624–631. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
De Luca A, Maiello MR, D'Alessio A,
Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT
signalling pathways: Role in cancer pathogenesis and implications
for therapeutic approaches. Expert Opin Ther Targets. 16(Suppl 2):
S17–S27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Steelman LS, Franklin RA, Abrams SL,
Chappell W, Kempf CR, Bäsecke J, Stivala F, Donia M, Fagone P,
Nicoletti F, et al: Roles of the Ras/Raf/MEK/ERK pathway in
leukemia therapy. Leukemia. 25:1080–1094. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar
|
|
9
|
Holderfield M, Deuker MM, McCormick F and
McMahon M: Targeting RAF kinases for cancer therapy: BRAF-mutated
melanoma and beyond. Nat Rev Cancer. 14:455–467. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Y, Kaiser CE, Frett B and Li HY:
Targeting mutant KRAS for anticancer therapeutics: A review of
novel small molecule modulators. J Med Chem. 56:5219–5230. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsai JH, Huang WC, Jhuang JY, Jeng YM,
Cheng ML, Chiu HY, Kuo KT and Liau JY: Frequent activating HRAS
mutations in trichilemmoma. Br J Dermatol. 171:1073–1077. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Trietsch MD, Spaans VM, ter Haar NT, Osse
EM, Peters AA, Gaarenstroom KN and Fleuren GJ: CDKN2A(p16) and HRAS
are frequently mutated in vulvar squamous cell carcinoma. Gynecol
Oncol. 135:149–155. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ojesina AI, Lichtenstein L, Freeman SS,
Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, Cherniack AD, Ambrogio
L, Cibulskis K, Bertelsen B, et al: Landscape of genomic
alterations in cervical carcinomas. Nature. 506:371–375. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bell DBA, Birrer M, Chien J, Cramer D, Dao
F, Dhir R, DiSaia P, Gabra H, Glenn P, Godwin A, et al Cancer
Genome Atlas Research Network: Integrated genomic analyses of
ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar
|
|
15
|
Wang F, Zou Y, Liu FY, Yu XH, Huang H,
Zhang N, Qi YY, Liu RF, Liu XY, Chen J, et al: Infrequent mutations
of the PPP2R1A and PPP2R1B genes in patients with ovarian cancer.
Mol Med Rep. 7:1826–1830. 2013.PubMed/NCBI
|
|
16
|
Zou Y, Wang F, Liu FY, Huang MZ, Li W,
Yuan XQ, Huang OP and He M: RNF43 mutations are recurrent in
Chinese patients with mucinous ovarian carcinoma but absent in
other subtypes of ovarian cancer. Gene. 531:112–116. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zou Y, Liu FY, Liu H, Wang F, Li W, Huang
MZ, Huang Y, Yuan XQ, Xu XY, Huang OP, et al: Frequent POLE1
p.S297F mutation in Chinese patients with ovarian endometrioid
carcinoma. Mutat Res. 761:49–52. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zou Y, Huang MZ, Liu FY, Yang BC, Wang LQ,
Wang F, Yu XH, Wan L, Wan XD, Xu XY, et al: Absence of DICER1,
CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations in
patients with various subtypes of ovarian carcinomas. Biomed Rep.
3:33–37. 2015.
|
|
19
|
Guex N and Peitsch MC: SWISS-MODEL and the
Swiss- PdbViewer: An environment for comparative protein modeling.
Electrophoresis. 18:2714–2723. 1997. View Article : Google Scholar
|
|
20
|
Krauthammer M, Kong Y, Ha BH, Evans P,
Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, et
al: Exome sequencing identifies recurrent somatic RAC1 mutations in
melanoma. Nat Genet. 44:1006–1014. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Muzny DMBM, Chang K, Dinh HH, Drummond JA,
Fowler G, Kovar CL, Lewis LR, Morgan MB, Newsham IF, Reid JG, et al
Cancer Genome Atlas Network: Comprehensive molecular
characterization of human colon and rectal cancer. Nature.
487:330–337. 2012. View Article : Google Scholar
|
|
22
|
Biankin AV, Waddell N, Kassahn KS, Gingras
MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J,
et al Australian Pancreatic Cancer Genome Initiative: Pancreatic
cancer genomes reveal aberrations in axon guidance pathway genes.
Nature. 491:399–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Landau DA, Carter SL, Stojanov P, McKenna
A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A,
Wang L, et al: Evolution and impact of subclonal mutations in
chronic lymphocytic leukemia. Cell. 152:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Goyal LD, Kaur S and Kawatra K: Malignant
mixed germ cell tumour of ovary - an unusual combination and review
of literature. J Ovarian Res. 7(91)2014. View Article : Google Scholar
|
|
25
|
Heravi-Moussavi A, Anglesio MS, Cheng SW,
Senz J, Yang W, Prentice L, Fejes AP, Chow C, Tone A, Kalloger SE,
et al: Recurrent somatic DICER1 mutations in nonepithelial ovarian
cancers. N Engl J Med. 366:234–242. 2012. View Article : Google Scholar
|
|
26
|
Witkowski L, Carrot-Zhang J, Albrecht S,
Fahiminiya S, Hamel N, Tomiak E, Grynspan D, Saloustros E, Nadaf J,
Rivera B, et al: Germline and somatic SMARCA4 mutations
characterize small cell carcinoma of the ovary, hypercalcemic type.
Nat Genet. 46:438–443. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ryland GL, Hunter SM, Doyle MA, Rowley SM,
Christie M, Allan PE, Bowtell DD, Gorringe KL and Campbell IG;
Australian Ovarian Cancer Study Group: RNF43 is a tumour suppressor
gene mutated in mucinous tumours of the ovary. J Pathol.
229:469–476. 2013. View Article : Google Scholar
|
|
28
|
Boyd J, Luo B, Peri S, Wirchansky B,
Hughes L, Forsythe C and Wu H: Whole exome sequence analysis of
serous borderline tumors of the ovary. Gynecol Oncol. 130:560–564.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pickering CR, Zhang J, Yoo SY, Bengtsson
L, Moorthy S, Neskey DM, Zhao M, Ortega Alves MV, Chang K, Drummond
J, et al: Integrative genomic characterization of oral squamous
cell carcinoma identifies frequent somatic drivers. Cancer Discov.
3:770–781. 2013. View Article : Google Scholar : PubMed/NCBI
|
